<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527878</url>
  </required_header>
  <id_info>
    <org_study_id>070218</org_study_id>
    <secondary_id>07-I-0218</secondary_id>
    <nct_id>NCT00527878</nct_id>
  </id_info>
  <brief_title>Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of ranitidine (Zantac) in patients with
      Hyper-IgE recurrent infection syndrome, a disease characterized by recurrent infections of
      the ears, sinuses, lungs and skin, and abnormal levels of the antibody immunoglobulin E
      (IgE).

      Patients age 2 and older who have Hyper-IgE recurrent infection syndrome and who have had
      chronic or frequent infections in the last 12 months may be eligible for this study.

      Participants are randomly assigned to take ranitidine or placebo in pill or liquid form twice
      a day for 12 months. In addition to treatment, patients undergo the following procedures
      during visits scheduled on day 0 of the study (baseline) and at 3, 12, 15 and 24 months.
      Evaluations at 6, 9, 18 and 21 months are by telephone.

        -  Medical history and physical examination - baseline and 3 and 24 months.

        -  Clinical severity score - baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months.

        -  Dermatology exam - baseline and 3, 12, 15 and 24 months.

        -  Pulmonary function test - baseline and 12 and 24 months.

        -  Chest CT - baseline and 12 and 24 months.

        -  Quality of life assessment - baseline and 3, 12, 15 and 24 months.

        -  Pregnancy testing - baseline and 3, 12, 15 and 24 months.

        -  HIV test - baseline and 12 and 24 months.

        -  Contraception evaluation - baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months.

        -  Missed school/work days assessment - baseline and 3, 12, 15 and 24 months.

        -  Medication adherence - baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months.

      In addition to the above procedures, participants who are not enrolled in study 00-I-0159
      have a baseline scoliosis series and genetic consult.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyper-immunoglobulin E (IgE) syndrome (HIES) is a rare primary immunodeficiency characterized
      by eczema, recurrent skin and lung infections, elevated serum IgE, and multiple connective
      tissue and skeletal abnormalities. The autosomal dominant form of HIES is caused primarily by
      a mutation in the STAT3 gene. Patients with HIES produce IgE antibodies specific for Candida
      albicans and Staphylococcus aureus, two of the common pathogens in this population. We
      hypothesize that the presence of pathogen-specific IgE, combined with continuous exposure to
      these ubiquitous agents, leads to chronic IgE-mediated histamine release from basophils and
      mast cells, with subsequent pathogen-specific immune tolerance and an increase in
      pathogen-specific T regulatory cells. We plan to test this hypothesis through clinical and
      immunologic evaluation of HIES patients before, during, and after histamine-2 receptor (H2)
      blocker therapy with ranitidine through a prospective, placebo-controlled crossover study. We
      chose this therapy because histamine has been shown to stimulate interleukin-10 (IL-10), a
      major down regulatory cytokine, through the H2 receptor, and clinical improvement has been
      observed in several patients treated with H2 blockers. Laboratory studies will include
      determinations of pathogen-specific immunoglobulin G4 (IgG4):IgE ratios, basophil activation,
      IL-10 producing regulatory T-cells, cellular proliferative responses to staphylococcal and
      candidal antigens, and functional testing of regulatory T-cells. Clinical evaluations will
      include comprehensive history and physical examination, dermatologic evaluation, genetic
      evaluation for clinical severity scoring of HIES, pulmonary function tests, and chest
      computerized tomography (CT) examination. Through this study, we will further our
      understanding of the immunologic abnormalities of HIES and determine whether a larger
      prospective, double-blind trial of H2 blockade as adjunctive therapy for HIES is indicated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to enroll adequate patient numbers due to small number of eligible patients
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Infections in Subjects With HIES.</measure>
    <time_frame>1 year on intervention</time_frame>
    <description>Patients received one year of treatment medication and one year of placebo. New infections (bacterial, fungal, viral or parasitic) were defined as those requiring an addition or change of an antimicrobial (including topical, oral or intravenous therapies) or those requiring a medical procedure (i.e., incision and drainage of a skin abscess, warm soaks to aid abscess drainage or sinus drainage).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New Skin Infections</measure>
    <time_frame>12 months placebo/12 months ranitidine</time_frame>
    <description>Patients reported the number of new skin infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Lung Infections</measure>
    <time_frame>12 months placebo and 12 months ranitidine</time_frame>
    <description>Number of new infection while on placebo or study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>one year on ranitidine and one year on placebo</time_frame>
    <description>Scoring that was completed every 3 months. Clinical severity scored had outcomes that could range from 0 to 121 with 0 being the least severe and 121 being the most severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>JOB's Syndrome</condition>
  <condition>Hyper-IgE Recurrent Infection Syndrome</condition>
  <condition>Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Placebo/Ranitidine crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients took placebo for 12 months and then ranitidine for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranitidine/placebo crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranitidine for one year followed by placebo for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine</intervention_name>
    <description>Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).</description>
    <arm_group_label>Placebo/Ranitidine crossover</arm_group_label>
    <arm_group_label>Ranitidine/placebo crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo/Ranitidine crossover</arm_group_label>
    <arm_group_label>Ranitidine/placebo crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Male and female patients with the diagnosis of Hyper IgE Recurrent Infection
                  (Job) syndrome. Mutations in the STAT3 gene account for the majority, if not all
                  cases of HIES. However as the full genetics of HIES remains unknown, we will use
                  clinical criteria, including the expert opinion of the investigators, as well as
                  a score greater than 40 by the diagnostic scoring system used in protocol
                  00-I-0159.

               2. A chronic (greater than 4 weeks duration) infection or greater than 2 acute
                  infections within the last 12 months. Acute infections can include but are not
                  limited to: pneumonia, abscesses, sinusitis, skin infections, mucocutaneous
                  candidiasis and ear infections. Chronic infections include continuous or
                  intermittent symptoms despite appropriate therapeutic interventions for at least
                  4 weeks, including but not limited to chronic lung infiltrates with productive
                  cough, chronic ear drainage despite topical therapy, chronic or intermittent
                  drainage from a single abscess site, and/or chronic signs of sinusitis on sinus
                  CT scan.

               3. Patients aged 2 years and above. There is no upper age limit. We are excluding
                  children less than 2 years of age, as we do not expect them to meet the first
                  inclusion criterion, having a score high enough to be diagnosed with HIES.

               4. Patients have to be at their own personal clinical baseline for at least 2 weeks
                  duration. Patients will not start the study medication during an acute
                  exacerbation of and infection.

               5. The patient or the patient's guardian will be willing and capable of providing
                  informed consent after initial counseling by clinical staff. Separate consent
                  forms for all interventional procedures will be obtained after explanation of the
                  specific procedure.

               6. Patients must agree to have blood stored for future studies of the immune system
                  and/or other medical conditions.

               7. Women of childbearing potential must agree to use adequate contraception
                  (hormonal or barrier method of birth control; abstinence) prior to study entry
                  and for the duration of study participation.

               8. Patients may be concurrently enrolled on other protocols as long as the Principal
                  Investigator (PI) is informed.

        EXCLUSION CRITERIA:

          1. Pregnancy. Ranitidine is pregnancy class B, and likely safe in pregnancy, but as this
             has not been studied, pregnant patients will be excluded. In addition, hormonal
             changes that occur during pregnancy may affect the skin manifestations and frequency
             of infection.

          2. Hypersensitivity to ranitidine or any of the ingredients in ranitidine.

          3. Pre-existing medications or conditions for which the investigators judge that
             ranitidine should not be given.

          4. Patient or investigators unwilling to stop baseline H2 receptor antagonist therapy
             (over the counter or prescription) such as Tagamet (Cimetidine), Pepcid (Famotidine),
             and Axid (Nizatidine). H2 receptor antagonist therapy must be stopped for 3 months
             prior to study initiation. Patients who are receiving H2 receptor antagonist therapy
             for gastritis, acid reflux, or peptic ulcer disease will be offered changing their
             regimen to a proton pump inhibitor or other non-H2 receptor antagonist therapy to
             allow for study enrollment (3 months after stopping the H2 receptor antagonist).

          5. Patients under the age of 2 years

          6. Patients with HIV, receiving chemotherapy or who have a malignancy.

          7. Any condition that in the judgment of the investigator would place the subject at
             undue risk or compromise the results or interpretation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, Miller JA, O'Connell AC, Puck JM. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med. 1999 Mar 4;340(9):692-702.</citation>
    <PMID>10053178</PMID>
  </reference>
  <reference>
    <citation>Davis SD, Schaller J, Wedgwood RJ. Job's Syndrome. Recurrent, &quot;cold&quot;, staphylococcal abscesses. Lancet. 1966 May 7;1(7445):1013-5.</citation>
    <PMID>4161105</PMID>
  </reference>
  <reference>
    <citation>Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics. 1972 Jan;49(1):59-70.</citation>
    <PMID>5059313</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2007</study_first_submitted>
  <study_first_submitted_qc>September 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <results_first_submitted>February 1, 2013</results_first_submitted>
  <results_first_submitted_qc>February 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2013</results_first_posted>
  <last_update_submitted>February 1, 2013</last_update_submitted>
  <last_update_submitted_qc>February 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <name_title>Steven M. Holland, M.D./National Institute of Allergy and Infectious Diseases</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Hyper-IgE Recurrent Infection Syndrome</keyword>
  <keyword>Ranitidine Therapy</keyword>
  <keyword>Job's Syndrome</keyword>
  <keyword>Cross-Over Study</keyword>
  <keyword>Double-Blind Placebo Controlled</keyword>
  <keyword>Hyper-IgE Syndrome</keyword>
  <keyword>Job Syndrome</keyword>
  <keyword>Immune Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Job Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>16 participants were screened but only 14 participants were randomized. Two individuals decided not to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Ranitidine</title>
          <description>Ranitidine will be dosed orally at 150 mg twice daily for adults, and at 2-4 mg/kg/dose twice daily for children with a maximum dose of 150 mg twice daily. Liquid formulations will be provided for individuals unable to swallow pills. Subjects will be randomized to receive placebo for 12 months followed by 12 months of the ranitidine.</description>
        </group>
        <group group_id="P2">
          <title>Ranitidine/Placebo</title>
          <description>Ranitidine will be dosed orally at 150 mg twice daily for adults, and at 2-4 mg/kg/dose twice daily for children with a maximum dose of 150 mg twice daily. Liquid formulations will be provided for individuals unable to swallow pills. Subjects will be randomized to receive ranitidine for 12 months followed by 12 months of the ranitidine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants whether or not they were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Patients</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Infections in Subjects With HIES.</title>
        <description>Patients received one year of treatment medication and one year of placebo. New infections (bacterial, fungal, viral or parasitic) were defined as those requiring an addition or change of an antimicrobial (including topical, oral or intravenous therapies) or those requiring a medical procedure (i.e., incision and drainage of a skin abscess, warm soaks to aid abscess drainage or sinus drainage).</description>
        <time_frame>1 year on intervention</time_frame>
        <population>Patients that completed both arms of the study (24 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Crossover study in which patients received one year of placebo and one year of ranitidine. This analysis will include the placebo for both arms.</description>
          </group>
          <group group_id="O2">
            <title>Ranitidine</title>
            <description>Crossover study in which patients received one year of placebo and one year of ranitidine. This analysis will include the treatment for both arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infections in Subjects With HIES.</title>
          <description>Patients received one year of treatment medication and one year of placebo. New infections (bacterial, fungal, viral or parasitic) were defined as those requiring an addition or change of an antimicrobial (including topical, oral or intravenous therapies) or those requiring a medical procedure (i.e., incision and drainage of a skin abscess, warm soaks to aid abscess drainage or sinus drainage).</description>
          <population>Patients that completed both arms of the study (24 months)</population>
          <units>infections</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="25"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Skin Infections</title>
        <description>Patients reported the number of new skin infections</description>
        <time_frame>12 months placebo/12 months ranitidine</time_frame>
        <population>Patients that completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Crossover study in which patients received one year of placebo and one year of ranitidine. This analysis will include the placebo for both arms.</description>
          </group>
          <group group_id="O2">
            <title>Ranitidine</title>
            <description>Crossover study in which patients received one year of placebo and one year of ranitidine. This analysis will include the treatment for both arms.</description>
          </group>
        </group_list>
        <measure>
          <title>New Skin Infections</title>
          <description>Patients reported the number of new skin infections</description>
          <population>Patients that completed the study</population>
          <units>skin infections</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Lung Infections</title>
        <description>Number of new infection while on placebo or study drug</description>
        <time_frame>12 months placebo and 12 months ranitidine</time_frame>
        <population>Patients who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Crossover study in which patients received one year of placebo and one year of ranitidine. This analysis will include the placebo for both arms.</description>
          </group>
          <group group_id="O2">
            <title>Ranitidine</title>
            <description>Crossover study in which patients received one year of placebo and one year of ranitidine. This analysis will include the treatment for both arms.</description>
          </group>
        </group_list>
        <measure>
          <title>New Lung Infections</title>
          <description>Number of new infection while on placebo or study drug</description>
          <population>Patients who completed the study</population>
          <units>new lung infections</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Severity Score</title>
        <description>Scoring that was completed every 3 months. Clinical severity scored had outcomes that could range from 0 to 121 with 0 being the least severe and 121 being the most severe.</description>
        <time_frame>one year on ranitidine and one year on placebo</time_frame>
        <population>Patients who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Crossover study in which patients received one year of placebo and one year of ranitidine. This analysis will include the placebo for both arms.</description>
          </group>
          <group group_id="O2">
            <title>Ranitidine</title>
            <description>Crossover study in which patients received one year of placebo and one year of ranitidine. This analysis will include the treatment for both arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Severity Score</title>
          <description>Scoring that was completed every 3 months. Clinical severity scored had outcomes that could range from 0 to 121 with 0 being the least severe and 121 being the most severe.</description>
          <population>Patients who completed the study</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="3.2" upper_limit="27.5"/>
                    <measurement group_id="O2" value="8.5" lower_limit="3.5" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not analyzed for each participant as 7 participants did not complete the study and so we were not able to evaluate for adverse events for both placebo and study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>this was a crossover study and patients received both placebo and study drug (ranitidine), both of which for 12 months, unless they terminated the study.</description>
        </group>
        <group group_id="E2">
          <title>Ranitidine</title>
          <description>This was a crossover study and patients received 12 months of ranitidine and 12 months of placebo, unless they terminated the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <description>Not thought to be related to study</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>Thought to be related to underlying disease</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>Thought to be related to underlying study</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin abscess</sub_title>
                <description>thought to be related to underlying disease</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>groin abscess</sub_title>
                <description>thought to be related to underlying disease</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>central line infection</sub_title>
                <description>Not thought to be related to study medication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <description>Not thought to be related</description>
                <counts group_id="E1" events="1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>death from respiratory failure</sub_title>
                <description>patient with death presumed to be related to narcotics.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eyelid stye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>occult blood in stool</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dental problems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>tongue ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>elevated Liver function tests</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>otitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Streptococcal sore throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>arthralgias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alexandra Freeman MD, Staff Clinician, Lead Associate Investigator for Protocol</name_or_title>
      <organization>NIAID, NIH</organization>
      <phone>301-594-9045</phone>
      <email>freemaal@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

